David Shaw’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $208M | Buy |
1,094,593
+1,069,588
| +4,277% | +$201M | 0.1% | 214 |
|
|
2026
Q1 | $4.93M | Buy |
25,005
+4,286
| +21% | +$826K | ﹤0.01% | 2186 |
|
|
2025
Q4 | $3.81M | Sell |
20,719
-95,097
| -82% | -$16.7M | ﹤0.01% | 2538 |
|
|
2025
Q3 | $17.8M | Sell |
115,816
-836,656
| -88% | -$127M | 0.01% | 1260 |
|
|
2025
Q2 | $133M | Buy |
952,472
+103,576
| +12% | +$14.5M | 0.09% | 261 |
|
|
2025
Q1 | $125M | Sell |
848,896
-1,564,269
| -65% | -$226M | 0.11% | 218 |
|
|
2024
Q4 | $316M | Buy |
2,413,165
+1,617,437
| +203% | +$226M | 0.23% | 78 |
|
|
2024
Q3 | $124M | Buy |
795,728
+779,053
| +4,672% | +$126M | 0.11% | 221 |
|
|
2024
Q2 | $2.6M | Buy |
16,675
+8,315
| +99% | +$1.25M | ﹤0.01% | 2408 |
|
|
2024
Q1 | $1.13M | Sell |
8,360
-775,531
| -99% | -$103M | ﹤0.01% | 3012 |
|
|
2023
Q4 | $106M | Buy |
783,891
+423,751
| +118% | +$55.1M | 0.09% | 259 |
|
|
2023
Q3 | $48.8M | Buy |
360,140
+338,434
| +1,559% | +$46.2M | 0.05% | 437 |
|
|
2023
Q2 | $3.11M | Buy |
21,706
+18,575
| +593% | +$2.73M | ﹤0.01% | 2266 |
|
|
2023
Q1 | $435K | Sell |
3,131
-329,826
| -99% | -$44.4M | ﹤0.01% | 3618 |
|
|
2022
Q4 | $45.1M | Buy |
332,957
+158,022
| +90% | +$19.8M | 0.05% | 475 |
|
|
2022
Q3 | $19.2M | Buy |
174,935
+170,013
| +3,454% | +$21.6M | 0.02% | 873 |
|
|
2022
Q2 | $650K | Sell |
4,922
-113,553
| -96% | -$14.9M | ﹤0.01% | 3929 |
|
|
2022
Q1 | $15.7M | Sell |
118,475
-291,997
| -71% | -$35M | 0.01% | 1205 |
|
|
2021
Q4 | $47.8M | Sell |
410,472
-178,080
| -30% | -$21M | 0.04% | 566 |
|
|
2021
Q3 | $70.7M | Buy |
588,552
+326,435
| +125% | +$38M | 0.06% | 375 |
|
|
2021
Q2 | $31.4M | Buy |
+262,117
| New | +$28.8M | 0.03% | 779 |
|
|
2021
Q1 | – | Sell |
-2,138,786
| Closed | -$214M | – | 4040 |
|
|
2020
Q4 | $214M | Buy |
2,138,786
+2,117,398
| +9,900% | +$224M | 0.19% | 90 |
|
|
2020
Q3 | $2.34M | Buy |
+21,388
| New | +$2.38M | ﹤0.01% | 2289 |
|
|
2019
Q3 | – | Sell |
-131,259
| Closed | -$10.8M | – | 3804 |
|
|
2019
Q2 | $10.8M | Buy |
131,259
+53,464
| +69% | +$4.19M | 0.01% | 1088 |
|
|
2019
Q1 | $6.29M | Sell |
77,795
-57,482
| -42% | -$4.53M | 0.01% | 1393 |
|
|
2018
Q4 | $10.3M | Buy |
+135,277
| New | +$10.6M | 0.01% | 1077 |
|
|
2018
Q2 | – | Sell |
-5,405
| Closed | -$378K | – | 3689 |
|
|
2018
Q1 | $378K | Sell |
5,405
-1,204
| -18% | -$83.4K | ﹤0.01% | 3030 |
|
|
2017
Q4 | $459K | Buy |
+6,609
| New | +$446K | ﹤0.01% | 3020 |
|
|
2017
Q3 | – | Sell |
-24,706
| Closed | -$1.68M | – | 3438 |
|
|
2017
Q2 | $1.68M | Sell |
24,706
-41,695
| -63% | -$2.72M | ﹤0.01% | 2083 |
|
|
2017
Q1 | $4.13M | Buy |
66,401
+52,251
| +369% | +$3.04M | 0.01% | 1406 |
|
|
2016
Q4 | $773K | Buy |
+14,150
| New | +$803K | ﹤0.01% | 2615 |
|
|
2016
Q3 | – | Sell |
-242,808
| Closed | -$14.7M | – | 3366 |
|
|
2016
Q2 | $14.7M | Sell |
242,808
-73,489
| -23% | -$4.27M | 0.03% | 673 |
|
|
2016
Q1 | $17.8M | Buy |
316,297
+237,327
| +301% | +$14.3M | 0.03% | 589 |
|
|
2015
Q4 | $5.36M | Buy |
78,970
+62,444
| +378% | +$4.09M | 0.01% | 1359 |
|
|
2015
Q3 | $1.05M | Sell |
16,526
-145,437
| -90% | -$9.57M | ﹤0.01% | 2570 |
|
|
2015
Q2 | $10.3M | Buy |
161,963
+84,278
| +108% | +$5.77M | 0.02% | 1006 |
|
|
2015
Q1 | $5.32M | Buy |
+77,685
| New | +$5.4M | 0.01% | 1341 |
|
|
2014
Q4 | – | Sell |
-110,929
| Closed | -$7.94M | – | 4003 |
|
|
2014
Q3 | $7.92M | Buy |
110,929
+36,021
| +48% | +$2.64M | 0.01% | 1236 |
|
|
2014
Q2 | $5.57M | Buy |
74,908
+5,268
| +8% | +$381K | 0.01% | 1542 |
|
|
2014
Q1 | $4.52M | Buy |
+69,640
| New | +$4.5M | 0.01% | 1673 |
|
|
2013
Q4 | – | Sell |
-24,496
| Closed | -$1.33M | – | 4446 |
|
|
2013
Q3 | $1.27M | Sell |
24,496
-296,831
| -92% | -$14.9M | ﹤0.01% | 2824 |
|
|
2013
Q2 | $15.2M | Buy |
+321,327
| New | +$16.4M | 0.03% | 641 |
|
Other funds holding AZN
EP
IA
David Shaw's AZN Position: Q2 2026 in Review
David Shaw increased its AstraZeneca (AZN) stake by 4,277% in Q2 2026, buying an estimated $201M and bringing the position to 1,094,593 shares worth $208M. The position accounts for 0.1% of the portfolio, ranked #214.
David Shaw first reported a position in AZN in Q2 2013 and has held it in 42 quarters since. The position peaked at $316M in Q4 2024. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.
- David Shaw held 1,094,593 shares of AstraZeneca worth $208M as of Q2 2026.
- David Shaw bought 1,069,588 AstraZeneca shares in Q2 2026, an estimated $201M.
- AstraZeneca made up 0.1% of David Shaw's portfolio in Q2 2026, its #214 holding.
- David Shaw first reported a position in AstraZeneca in Q2 2013 and has held it in 42 quarters since.
- David Shaw's AstraZeneca position peaked at $316M in Q4 2024.
- 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.
Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.